Upperton Opens New Development and GMP Manufacturing Facility
Upperton Pharma Solutions was joined by Sarah Gilbert, Professor and co-creator of the Oxford/AstraZeneca COVID-19 vaccine for the official opening of its new development and GMP manufacturing facility in Nottingham, UK.
UK-based contract development and manufacturing organization (CDMO) Upperton Pharma Solutions recently celebrated the official opening of a new 50,000 square foot development and GMP manufacturing facility in Nottingham.
Nikki Whitfield, CEO of Upperton Pharma Solutions, commented, “This celebration marks another milestone in our incredible growth journey as a business. We are looking forward to officially opening our doors to customers and offering a single site solution for development and GMP manufacturing.”
The new facility contains ten GMP manufacturing suites, cutting-edge quality control laboratories, and formulation development capabilities equipped with a pilot plant. The facility enables Upperton to offer customers early formulation development to clinical trial supplies from Phase 1 to Phase 3 and niche scale commercial manufacturing all on one site.
“It was a pleasure to join Upperton for the grand opening of their new facility”, said Sarah Gilbert, co-creator of the Oxford/AstraZeneca COVID-19 vaccine. “During the pandemic we saw the importance of academia and industry working closely together to deliver life-saving vaccines and treatments. Upperton’s expansion into this new site is a great example of the crucial role UK-based pharmaceutical organisations have to play in addressing global health challenges. I look forward to collaborating with Upperton in the future.”
The official opening marks another milestone for Upperton following the announcement and ongoing build of a new sterile facility on the same site, for the manufacturing of aseptic and terminally sterilized small-volume liquids for parenteral, ocular, and pulmonary delivery due for completion at the end of 2024.
Company
Upperton Pharma SolutionsAlbert Einstein Centre, Nottingham Science Park
NG7 2TN Nottingham
UK
most read
Oxea Appoints Michael McHenry as New Chief Executive Officer
German oxo-chemicals manufacturer Oxea has appointed Michael McHenry as its new CEO with effect from August 15, 2025.
Roche and Zealand Pharma Collaborate on Weight Management Drug
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Boehringer Ingelheim Paves the Way for Important Market Launches
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
Novo Nordisk Invests $1.09 Billion in Brazil
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
BASF Divests Two Joint Ventures in China
BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.